Last reviewed · How we verify
Bupivacain 0.125%
At a glance
| Generic name | Bupivacain 0.125% |
|---|---|
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Supra vs Infra Inguinal Fascia Iliaca Blocks for Spinal Positioning and Analgesia in Lower Limb Surgery (PHASE2, PHASE3)
- Comparative Study on the Effect of Quadratus Lumborum Block Versus Intrathecal Morphine on the Incidence of Chronic Pain Post Caesarean Section in a University Hospital of Middle-income Country (NA)
- Postoperative Pain Scores and Opioid Consumption in Video Assisted Thoracic Surgery (NA)
- Presternal Magnesium With Bupivacain Versus Bupivacain Only for Postoperative Pain Relief in Open Heart Surgery (NA)
- Postoperative Pain Alleviation in Open Heart Surgery (NA)
- Effects of Thoracic Epidural Administered Ropivacaine Versus Bupivacaine on Bladder Function (PHASE4)
- Transversus Abdominis Plane Block for Pain Relieve in Children Undergoing Groin Surgery (PHASE4)
- Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacain 0.125% CI brief — competitive landscape report
- Bupivacain 0.125% updates RSS · CI watch RSS
- Insel Gruppe AG, University Hospital Bern portfolio CI